[Specific in situ labeling of apoptosis shows different rates of programmed cell death in non-Hodgkin lymphomas].
Two new techniques were used to quantify cell death (i.e. DNA fragmentation) in situ: (1) 3' overhangs of the fragmented DNA were end labelled with biotin-7-dATP and TdT (peroxidase/DAB). (2) In situ nick translation (ISNT) was performed with DNA polymerase 1 and biotin-7-dATP, to label single strand segments of DNA (peroxidase/DAB). Both methods were tested to be negative in ischemic and tumor necrosis, and negative for mitotic figures. In 26 centroblastic Non Hodgkin lymphomas (CB) (monomorphous subtype [n = 9], polymorphous subtype [n = 7], secondary [n = 10]), 14 chronic lymphocytic leukemias and two immunocytomas these methods were employed to quantify the rate of cell death. ISNT proved to be more sensitive than end labelling. By ISNT, CB had a mean cell death rate of 250/10HPF (monomorphous type: 429/10HPF, polymorphous type: 222/10HPF, secondary: 111/10HPF). CLL showed a significantly lower rate (28/10HPF). These data suggest, that the low rate of cell turnover in CLL is indicated by a low rate of cell proliferation and a low rate of programmed cell death. In CB the high proliferation rate was accompanied by a high level of cell death. In CB/monomorphous a high turnover state with a very high proliferation and cell death rate was found, whereas CB/polymorphous represents an expansive state as indicated by a lower rate of cell death. CB/secondary showed almost no programmed cell death and therefore was interpreted as a high expansive state neoplasia.
Funk
A
A
Institut für Pathologie, Technischen Universität München.
Rudel
J
J
Fellbaum
C
C
Höfler
H
H
D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000032:analysis; D002455:Cell Division; D004249:DNA Damage; D004256:DNA Polymerase I / Q000378:metabolism; D004273:DNA, Neoplasm / Q000032:analysis*; D005821:Genetic Techniques; D006801:Humans; D007202:Indicators and Reagents; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000145:classification / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000145:classification / Q000473:pathology*; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D007202:Indicators and Reagents; D004256:DNA Polymerase I
Spezifische in situ Markierung von Apoptosen zeigt unterschiedliche Raten von programmiertem Zelltod in Non Hodgkin Lymphomen.